-
1.发明公开公开(公告)号：US20240208956A1
公开(公告)日：2024-06-27
申请号：US18286037
申请日：2022-04-07
IPC分类号： C07D413/14 , A61K31/4245 , A61K31/438 , A61K31/4439 , A61K31/496 , A61K31/4995 , A61K31/5377 , C07D413/12 , C07D417/14 , C07D471/10 , C07D487/08 , C07D487/10 , C07D491/107
CPC分类号： C07D413/14 , A61K31/4245 , A61K31/438 , A61K31/4439 , A61K31/496 , A61K31/4995 , A61K31/5377 , C07D413/12 , C07D417/14 , C07D471/10 , C07D487/08 , C07D487/10 , C07D491/107
摘要： The present invention relates to a novel 1,3,4-oxadiazole thiocarbonyl compound having a histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof, pharmaceutically acceptable salts thereof, a use thereof for preparing a medicament, a pharmaceutical composition containing the same, a therapeutic method using the composition, and a preparation method thereof, wherein a novel compound having a selective HDAC6 inhibitory activity is represented by formula I.
-
公开(公告)号：US11826460B2
公开(公告)日：2023-11-28
申请号：US17261801
申请日：2019-06-27
发明人： Byoung Ki Ahn , So Hyun Park
IPC分类号： A61K31/568 , A61K47/02 , A61K47/14 , A61K47/44 , A61K9/00
CPC分类号： A61K9/0019 , A61K31/568 , A61K47/02 , A61K47/14 , A61K47/44
摘要： The present invention relates to an injectable composition of testosterone ester for the treatment of testosterone deficiency. Particularly, the present invention relates to a pharmaceutical composition comprising testosterone undecanoate, which is capable of increasing the convenience for use in injection with the low viscosity and injection force, and has improved stability.
-
3.发明公开公开(公告)号：US20230295142A1
公开(公告)日：2023-09-21
申请号：US18024081
申请日：2021-09-01
发明人： Chang Sik Lee , Jung Taek Oh , Hokeun Yun , Hyeseung Song , Hyunjin Michael Kim
IPC分类号： C07D413/14 , C07D413/10 , C07D487/10
CPC分类号： C07D413/14 , C07D413/10 , C07D487/10
摘要： The present invention relates to a novel compound having a selective HDAC6 inhibitory activity, stereoisomers thereof, pharmaceutically acceptable salts thereof, a use thereof in preparation of a therapeutic medicament, a pharmaceutical composition containing the same, a therapeutic method using the composition, and a method for preparing the same, wherein the novel compound having the selective HDAC6 inhibitory activity is represented by chemical formula (I) below.
-
公开(公告)号：US20230278995A1
公开(公告)日：2023-09-07
申请号：US17995947
申请日：2021-04-12
IPC分类号： C07D413/12 , C07D413/14
CPC分类号： C07D413/12 , C07D413/14
摘要： The present invention relates to a novel compound having a histone deacetylase 6 (HDAC6) inhibitory activity, an optical isomer thereof or a pharmaceutically acceptable salt thereof, the use thereof for preparing a therapeutic medicament, a pharmaceutical composition containing the same, and a treatment method using the composition, and a preparation method thereof. The novel compound, the optical isomer thereof, or the pharmaceutically acceptable salt thereof according to the present invention has the HDAC6 inhibitory activity, which is effective in the prevention or treatment of HDAC6-mediated diseases including cancer, inflammatory diseases, autoimmune diseases, neurological or neurodegenerative diseases.
-
公开(公告)号：US20230248801A1
公开(公告)日：2023-08-10
申请号：US18010399
申请日：2021-06-29
发明人： Jin Young Ko , Sung Bum Jung , Sang Myoung Noh , Jong Lae Lim
摘要： An injectable composition of the present invention has remarkably increased safety by forming, into a composition, a sorbitan unsaturated fatty acid ester comprising g a polar head group with two or more —OH (hydroxyl) groups, is in a liquid phase in a phase where an aqueous fluid is absent so as to be easily applied to pharmaceutical preparations in dosage forms, and forms a liquid crystal in an aqueous fluid phase so that sustained-release effects of GnRH analogue, which is used as a pharmaceutically active substance in vivo, are exhibited. In addition, in an injectable composition of the present invention, a sustained-release lipid initial preparation comprising GnRH analogue includes water, and thus a liquid injectable agent forms a liquid crystal gel immediately after administration, so that the effects of reducing initial release rate and remarkably increasing sustained-release properties of the drug are exhibited.
-
公开(公告)号：US20230079386A1
公开(公告)日：2023-03-16
申请号：US17615363
申请日：2020-05-29
发明人： Chang Sik Lee , Jung Taek Oh , Hokeun Yun , Hyeseung Song , Hyunjin Michael Kim
IPC分类号： A61K31/4439 , A61K31/4245 , A61K31/437 , A61K31/4725 , A61K31/506 , A61K31/517 , A61K31/496 , A61K31/5377
摘要： The present invention relates to novel compounds having a histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, a medicinal use thereof, and a method for preparing the same. The novel compounds according to the present invention, stereoisomers thereof or pharmaceutically acceptable salts thereof have the histone deacetylase 6 (HDAC6) inhibitory activity, and are effective in preventing or treating HDAC6-related diseases, comprising infectious diseases; neoplasm; endocrinopathy; nutritional and metabolic diseases; mental and behavioral disorders; neurological diseases; eye and ocular adnexal diseases; circulatory diseases; respiratory diseases; digestive diseases; skin and subcutaneous tissue diseases; musculoskeletal system and connective tissue diseases; and teratosis or deformities, or chromosomal aberration.
-
公开(公告)号：US11571426B2
公开(公告)日：2023-02-07
申请号：US16766578
申请日：2018-11-23
发明人： Young Il Choi , Nina Ha , Daekwon Bae
IPC分类号： A61K31/5375 , A61P37/02 , A61K31/397 , A61K31/495 , A61K31/5377
摘要： The present invention relates to a pharmaceutical composition for preventing or treating lupus, containing a compound represented by a formula I, an optical isomer thereof or a pharmaceutically acceptable salt thereof as an effective component, as well as a treatment method using the compound, and use of the compound in the manufacture of a medicament for treating lupus. The pharmaceutical composition according to the present invention shows an excellent effect of preventing or treating lupus.
-
公开(公告)号：US11420950B2
公开(公告)日：2022-08-23
申请号：US15575672
申请日：2016-05-20
发明人： Changsik Lee , Jaekwang Lee , Hyeseung Song , Daekwon Bae , Nina Ha , Hyang Kim, II
IPC分类号： C07D295/215 , A61P37/00 , A61P9/00 , A61P35/00 , C07D241/04 , C07D471/10 , C07D211/18 , C07D211/22 , C07D211/58 , C07D211/62 , C07D213/36 , C07D295/205 , C07D211/96 , C07D211/54
摘要： The present invention relates to novel heterocyclicalkyl derivatives having histone deacetylase (HDAC) inhibitory activity, optical isomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel heterocyclicalkyl derivatives. The novel heterocyclicalkyl derivatives according to the present invention are selective histone deacetylase (HDAC) inhibitors, and may be effectively used for the treatment of histone deacetylase-mediated diseases, such as cell proliferative diseases, inflammatory diseases, autosomal dominant diseases, genetic metabolic diseases, autoimmune diseases, acute/chronic neurological disease, hypertrophy, heart failure, ocular diseases, or neurodegenerative diseases.
-
公开(公告)号：US20220233514A1
公开(公告)日：2022-07-28
申请号：US17270263
申请日：2019-07-26
发明人： Jong Seo Choi , Min Soo Kim , Shin Jung Park , Jong Lae Lim
IPC分类号： A61K31/4439 , A61K9/16 , A61K9/50 , A61K9/20 , A61K9/28
摘要： The present invention relates to a pharmaceutical preparation comprising omeprazole, an enantiomer thereof or a pharmaceutically acceptable salt thereof, and sodium bicarbonate, and a method for preparing the same. Specifically, the present invention relates to a pharmaceutical preparation in which sodium bicarbonate is first disintegrated so as to raise pH, and then omeprazole is dissolved such that the release properties of an active ingredient are improved, and thus the dissolution pattern and bioavailability of a drug can be enhanced.
-
公开(公告)号：US11318215B2
公开(公告)日：2022-05-03
申请号：US14764156
申请日：2014-02-28
发明人： Ho Young Hwang , Ji Hye Hwang , Young Nam Lee , Sang Myoung Noh , Min Hyo Ki
IPC分类号： A61K9/00 , A61K47/00 , A61K48/00 , A61K9/19 , A61K31/722 , A61K9/127 , C12N15/11 , A61K9/14 , A61K31/7088 , A61K31/713 , A61K47/14 , A61K47/24 , A61K47/26 , A61K47/28 , A61K47/36 , C12N15/113
摘要： Disclosed herein is a composition for gene delivery which forms into liquid crystals in an aqueous fluid including chitosan and a liquid crystal formation material. The composition of the present invention including chitosan and a liquid crystal formation material improves the relatively low binding strength between chitosan and a gene, and also considerably increases the stability of a chitosan nanocomposite in blood serum, thereby performing highly efficient gene delivery and providing excellent stability, thus being useful as a gene therapeutic agent.
-
-
-
-
-
-
-
-
-
搜索结果
93 条记录 (耗时 0.042 秒)
